Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OKYO
stocks logo

OKYO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast OKYO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKYO is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast OKYO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKYO is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.010
sliders
Low
7.00
Averages
7.00
High
7.00
Current: 2.010
sliders
Low
7.00
Averages
7.00
High
7.00
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$7
2025-02-18
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$7
2025-02-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$7
2025-02-14
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$7
2025-02-14
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$7
2025-02-10
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$7
2025-02-10
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for OKYO Pharma Ltd (OKYO.O) is -10.86, compared to its 5-year average forward P/E of -5.65. For a more detailed relative valuation and DCF analysis to assess OKYO Pharma Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.65
Current PE
-10.86
Overvalued PE
-1.62
Undervalued PE
-9.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.76
Undervalued EV/EBITDA
-5.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

OKYO News & Events

Events Timeline

(ET)
2025-09-22
08:38:55
Okyo Pharma reveals next steps in the development of urcosimod
select
2025-07-17 (ET)
2025-07-17
09:12:05
Okyo Pharma receives $1.9M in non-dilutive funding
select
2025-07-16 (ET)
2025-07-16
09:24:08
Okyo Pharma reports Phase 2 clinical trial results for urcosimod
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Newsfilter
PinnedOKYO Pharma Completes NCP Trial and Sees Shareholder Increase
  • Shareholder Increase: Panetta Partners Limited acquired 27,051 shares of OKYO, bringing Gabriele Cerrone's total holdings to 10,491,746 shares, reflecting confidence in the company's future prospects.
  • Drug Development Progress: OKYO's urcosimod has just completed a Phase 2 clinical trial for neuropathic corneal pain, demonstrating statistical significance across multiple endpoints, indicating potential market opportunities.
  • Innovative Treatment Solution: Urcosimod, a novel long-acting drug developed using membrane-anchored peptide technology, aims to enhance efficacy in the ocular environment, potentially addressing existing treatment gaps.
  • Market Positioning: OKYO focuses on developing innovative therapies for neuropathic corneal pain and dry eye disease, and with the success of its clinical trials, it is expected to enhance its competitiveness in the biopharmaceutical market.
[object Object]
Preview
9.0
12-03Globenewswire
OKYO Pharma Completes NCP Trial and Sees Shareholder Increase
  • Shareholder Increase: Gabriele Cerrone, through Panetta Partners Limited, acquired 27,051 shares of OKYO, raising his total holdings to 10,491,746 shares, reflecting confidence in the company's future prospects.
  • Clinical Trial Progress: OKYO has just completed a randomized controlled trial of urcosimod for neuropathic corneal pain, indicating potential efficacy in alleviating ocular pain, which could open new market opportunities for the company.
  • Innovative Drug Development: Urcosimod, a novel long-acting drug developed using membrane-anchored peptide technology, has demonstrated anti-inflammatory and pain-reducing activities in mouse models, potentially paving the way for advancements in ocular disease treatment.
  • Market Outlook: With no FDA-approved therapies for neuropathic corneal pain, OKYO's innovative treatment may fill a significant market gap, addressing patient needs and driving company growth.
[object Object]
Preview
9.5
11-19NASDAQ.COM
Nutex Health Rises 21% in After-Hours Trading Following Revenue Increase; Biotech Competitors Also See Gains on Tuesday

  • Nutex Health's Performance: Nutex Health Inc. saw a significant after-hours surge of 20.97% to $120.00 following a quarterly report that revealed a net loss of $17.7 million but a remarkable 220.7% increase in revenue year-over-year to $244.0 million.

  • Bullfrog AI Holdings Update: Bullfrog AI Holdings, Inc. gained 5.87% to $0.9798 in after-hours trading, likely due to investor positioning ahead of its upcoming technical presentation at the AI Drug Discovery & Development Summit 2025.

  • Clearside Biomedical's Recovery: Clearside Biomedical, Inc. rose 6.51% to $3.27 after reporting a narrower net loss of $5.97 million, although its revenue fell sharply to $201 thousand from $1.04 million a year ago.

  • Aytu BioPharma and OKYO Pharma Developments: Aytu BioPharma, Inc. climbed 8.91% to $2.20 after reporting a first-quarter net income increase, while OKYO Pharma Limited edged up 2.44% to $2.18, preparing for a presentation on its investigational drug candidate for neuropathic corneal pain.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is OKYO Pharma Ltd (OKYO) stock price today?

The current price of OKYO is 2.01 USD — it has increased 17.2 % in the last trading day.

arrow icon

What is OKYO Pharma Ltd (OKYO)'s business?

OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

arrow icon

What is the price predicton of OKYO Stock?

Wall Street analysts forecast OKYO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKYO is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is OKYO Pharma Ltd (OKYO)'s revenue for the last quarter?

OKYO Pharma Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is OKYO Pharma Ltd (OKYO)'s earnings per share (EPS) for the last quarter?

OKYO Pharma Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for OKYO Pharma Ltd (OKYO)'s fundamentals?

The market is revising No Change the revenue expectations for OKYO Pharma Limited (OKYO) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -11.06%.
arrow icon

How many employees does OKYO Pharma Ltd (OKYO). have?

OKYO Pharma Ltd (OKYO) has 4 emplpoyees as of December 05 2025.

arrow icon

What is OKYO Pharma Ltd (OKYO) market cap?

Today OKYO has the market capitalization of 75.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free